The human immunodeficiency virus (HIV) remains one of the most serious communicable diseases in Europe. According to the HIV/AIDS surveillance in Europe report by the European Centre for Disease Prevention and Control (ECDC), in 2020, around 15000 new HIV diagnoses were reported in 29 countries of the EU/EEA.
The EU has been investing in HIV/AIDS research and in the development of an effective vaccine for an AIDS-free Europe. Vaccines trigger an immune response, without causing the actual disease and providing protection against a potential infection.
To mark the World AIDS Vaccine Day, we highlight two projects funded under the Horizon 2020 programme that are developing research in this field:
The EAVI2020 project brings together leading HIV researchers from public organisations and biotech companies from Europe, Australia, Canada and the USA. The aim is to develop novel candidate vaccines that can succeed the first steps of development and be subject to human trials. Final results from the project are expected by the end of the year.
The EHVA project has 41 partners in the academic and industrial sectors from Europe, sub-Saharan Africa and North America. The project is working to promote a comprehensive approach to the development of an effective HIV vaccine and develop multidisciplinary research platforms.
Horizon 2020 (H2020) was the EU’s multiannual funding programme between 2014 and 2020. H2020 provided Research and Innovation (R&I) funding for multi-national collaboration projects as well as for individual researchers and SMEs via special funding instruments. Horizon 2020 continues asHorizon Europe programme, which will run until 2027.
- Publication date
- 18 May 2022
- European Health and Digital Executive Agency
- Programme Sector
- Horizon EuropeHorizon Europe Cluster 1: Health
- EUFundedMedical research